Research Analysts Offer Predictions for BEAM FY2025 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Wedbush raised their FY2025 EPS estimates for Beam Therapeutics in a report issued on Tuesday, November 4th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($4.57) for the year, up from their prior estimate of ($4.58). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics’ FY2026 earnings at ($6.08) EPS, FY2027 earnings at ($7.28) EPS, FY2028 earnings at ($6.22) EPS and FY2029 earnings at ($2.70) EPS.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.12). Beam Therapeutics had a negative net margin of 744.41% and a negative return on equity of 42.86%. The business had revenue of $9.70 million during the quarter, compared to the consensus estimate of $12.83 million. During the same period in the prior year, the firm earned ($1.17) EPS. The business’s revenue for the quarter was down 32.2% on a year-over-year basis.

Other equities analysts have also issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Beam Therapeutics in a research report on Friday, October 10th. Cantor Fitzgerald raised Beam Therapeutics to a “strong-buy” rating in a research note on Monday, July 21st. Barclays cut their price objective on shares of Beam Therapeutics from $25.00 to $21.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 6th. Finally, Jefferies Financial Group started coverage on shares of Beam Therapeutics in a research note on Thursday, October 9th. They set a “buy” rating and a $41.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $46.55.

Beam Therapeutics Trading Down 4.1%

NASDAQ BEAM opened at $22.21 on Thursday. The company has a market cap of $2.25 billion, a price-to-earnings ratio of -5.01 and a beta of 2.40. The company has a 50 day moving average of $23.98 and a 200-day moving average of $20.25. Beam Therapeutics has a 1-year low of $13.52 and a 1-year high of $35.25.

Institutional Trading of Beam Therapeutics

Several large investors have recently bought and sold shares of BEAM. Amalgamated Bank lifted its holdings in shares of Beam Therapeutics by 20.4% in the first quarter. Amalgamated Bank now owns 3,153 shares of the company’s stock worth $62,000 after acquiring an additional 534 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Beam Therapeutics by 2.2% during the 3rd quarter. Arizona State Retirement System now owns 26,771 shares of the company’s stock valued at $650,000 after purchasing an additional 580 shares during the last quarter. Martingale Asset Management L P increased its position in Beam Therapeutics by 5.2% during the 1st quarter. Martingale Asset Management L P now owns 12,038 shares of the company’s stock worth $235,000 after purchasing an additional 600 shares in the last quarter. Profund Advisors LLC lifted its stake in Beam Therapeutics by 3.0% in the 2nd quarter. Profund Advisors LLC now owns 26,183 shares of the company’s stock valued at $445,000 after purchasing an additional 758 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Beam Therapeutics by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,492 shares of the company’s stock valued at $205,000 after buying an additional 879 shares in the last quarter. 99.68% of the stock is owned by institutional investors and hedge funds.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.